Blood test could spare some cancer patients from harsh chemo

NCT ID NCT07340567

Not yet recruiting Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jan 24, 2026 · Last updated Apr 30, 2026 · Updated 13 times

Summary

This study looks at whether a simple blood test that detects tumor DNA can help doctors choose the right chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their blood test results. Those with no detectable tumor DNA may receive a milder chemo, while those with detectable DNA may get a stronger treatment. The goal is to see if this personalized approach improves survival and reduces unnecessary side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Institut Gustave Roussy

    Villejuif, 94800, France

    Contact Email: •••••@•••••

  • Onkologikliniken

    Uppsala, 75185, Sweden

    Contact Email: •••••@•••••

  • Sahlgrenska University Hospital

    Gothenburg, 41345, Sweden

    Contact Email: •••••@•••••

  • Skäne University Hospital

    Lund, 22185, Sweden

    Contact Email: •••••@•••••

  • Södersjukhuset

    Stockholm, 11883, Sweden

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.